Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors

Table 3

PR immunostaining and tumor phenotype in breast carcinoma of no special type, endometrioid endometrial carcinoma, high-grade serous ovarian carcinoma, and pancreatic neuroendocrine tumors.

				Progesterone receptor IHC result
				Negative (%)	Weak (%)	Moderate (%)	Strong (%)
Breast carcinoma of no special type	Tumor stage	pT1	749	36.7	9.9	11.9	41.5	<0.0001
		pT2	613	44.5	11.4	11.4	32.6
		pT3-4	122	54.9	11.5	4.1	29.5
	Grade	G1	183	23.0	10.9	12.6	53.6	<0.0001
		G2	799	34.3	10.4	13.4	41.9
		G3	543	59.7	10.7	7.2	22.5
	Nodal stage	pN0	682	40.2	8.8	9.8	41.2	<0.0001
		pN1	325	38.2	14.5	14.2	33.2
		pN2	114	47.4	13.2	10.5	28.9
		pN3	68	63.2	13.2	5.9	17.6
	Distant metastasis	pM0	199	38.7	7.5	10.6	43.2	<0.0001
		pM1	104	64.4	11.5	5.8	18.3
	HER2 status	Negative	850	37.8	10.5	11.1	40.7	<0.0001
		Positive	120	63.3	12.5	6.7	17.5
Endometrioid endometrial carcinoma	Tumor stage	pT1	94	29.8	22.3	13.8	34.0	0.8885
		pT2	23	34.8	17.4	8.7	39.1
		pT3-4	29	34.5	24.1	17.2	24.1
	Nodal stage	pN0	43	20.9	25.6	18.6	34.9	0.0327
		pN+	25	56.0	16.0	8.0	20.0
Serous ovarian carcinoma	Tumor stage	pT1	33	51.5	18.2	9.1	21.2	0.0750
		pT2	43	69.8	20.9	2.3	7.0
		pT3	267	72.3	18.7	3.7	5.2
	Nodal stage	pN0	83	65.1	26.5	6.0	2.4	0.0534
		pN1	171	76.0	15.8	2.3	5.8
Pancreatic neuroendocrine tumors	Tumor stage	pT1	10	40.0	10.0	20.0	30.0	0.0954
		pT2	15	26.7	33.3	6.7	33.3
		pT3	22	68.2	4.5	13.6	13.6
		pT4	2	0.0	50.0	0.0	50.0
	Nodal stage	pN0	24	29.2	20.8	16.7	33.3	0.0345
		pN+	21	71.4	9.5	9.5	9.5